The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis
Open accessAbstract
Background: Patients with metastatic breast cancer (MBC) are living longer, but the development of brain metastases often limits their survival. We conducted a systematic review and meta-analysis to determine the incidence of brain metastases in this patient population. Methods: Articles published from January 2000 to January 2020 were compiled from four databases using search terms related to breast cancer, brain metastasis, and incidence. The overall and per patient-year incidence of brain metastases were extracted from studies including patients with human epidermal growth factor receptor-2 positive (HER2+), triple negative, and hormone receptor (HR)+/hormone receptor negative (HER2−) MBC; pooled overall estimates for incidence were calculated using random effects models. Results: 937 articles were compiled, and 25 were included in the meta-analysis. Incidence of brain metastases in patients with HER2+ MBC, triple negative MBC, and HR+/HER2− MBC was reported in 17, 6, and 4 studies, respectively. The pooled cumulative incidence of brain metastases was 31% for the HER2+ subgroup (median follow-up: 30.7 months, IQR: 24.0–34.0), 32% for the triple negative subgroup (median follow-up: 32.8 months, IQR: 18.5–40.6), and 15% among patients with HR+/HER2− MBC (median follow-up: 33.0 months, IQR: 31.9–36.2). The corresponding incidences per patient-year were 0.13 (95% CI: 0.10–0.16) for the HER2+ subgroup, 0.13 (95%CI: 0.09–0.20) for the triple negative subgroup, and only 0.05 (95%CI: 0.03–0.08) for patients with HR+/HER2− MBC. Conclusion: There is a high incidence of brain metastases among patients with HER2+ and triple negative MBC. The utility of a brain metastases screening program warrants investigation in these populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis
DiSipio, T., Rye, S., Newman, B., & Hayes, S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70076-7 · Cited by 1,885
Cortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S.-A., Yusof, M. M., Gallardo, C., Lipatov, O., Barrios, C. H., Holgado, E., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32531-9 · Cited by 1,796
Bendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
Production of subject-verb agreement, tense, mood, and negation in Italian agrammatic aphasia.
Valantis, F., Carlo, S., Rita, C., Marialuisa, G., Serena, D. P., Giorgio, A., Francesca, B., Anna, M., Nicola, S., & Gabriele, M. (2015) · Frontiers in Psychology · doi:10.3389/conf.fpsyg.2015.65.00011 · Cited by 872
Dijkers, E. C., Oude Munnink, T. H., Kosterink, J. G., Brouwers, A. H., Jager, P. L., de Jong, J. R., van Dongen, G. A., Schröder, C. P., Lub-de Hooge, M. N., & de Vries, E. G. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.12 · Cited by 805
Miles, D., Gligorov, J., André, F., Cameron, D., Schneeweiss, A., Barrios, C., Xu, B., Wardley, A., Kaen, D., Andrade, L., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.05.801 · Cited by 734
Lin, N. U., Claus, E., Sohl, J., Razzak, A. R., Arnaout, A., & Winer, E. P. (2008) · Cancer · doi:10.1002/cncr.23930 · Cited by 727
Lin, N. U., Borges, V., Anders, C., Murthy, R. K., Paplomata, E., Hamilton, E., Hurvitz, S., Loi, S., Okines, A., Abramson, V., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00775 · Cited by 544
van Belle, G. (2002) · Wiley-Interscience eBooks · Cited by 461
Pestalozzi, B. C., Zahrieh, D., Price, K. N., Holmberg, S. B., Lindtner, J., Collins, J., Crivellari, D., Fey, M. F., Murray, E., Pagani, O., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl064 · Cited by 413
Krop, I. E., Lin, N. U., Blackwell, K., Guardino, E., Huober, J., Lu, M., Miles, D., Samant, M., Welslau, M., & Diéras, V. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu486 · Cited by 394
Brufsky, A. M., Mayer, M., Rugo, H. S., Kaufman, P. A., Tan-Chiu, E., Tripathy, D., Tudor, I. C., Wang, L. I., Brammer, M. G., Shing, M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2962 · Cited by 386
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
Clayton, A. J., Danson, S., Jolly, S., Ryder, W. D. J., Burt, P. A., Stewart, A. L., Wilkinson, P. M., Welch, R. S., Magee, B., Wilson, G., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601970 · Cited by 385
Montemurro, F., Delaloge, S., Barrios, C. H., Wuerstlein, R., Anton, A., Brain, E., Hatschek, T., Kelly, C. M., Peña-Murillo, C., Yilmaz, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.020 · Cited by 349
Gabos, Z., Sinha, R., Hanson, J., Chauhan, N., Hugh, J., Mackey, J. R., & Abdulkarim, B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0250 · Cited by 321
Awada, A., Colomer, R., Inoue, K., Bondarenko, I., Badwe, R. A., Demetriou, G., Lee, S.-C., Mehta, A. O., Kim, S.-B., Bachelot, T., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0237 · Cited by 305
Pestalozzi, B. C., & Brignoli, S. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2349 · Cited by 301
Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study
Martin, A. M., Cagney, D. N., Catalano, P. J., Warren, L. E., Bellon, J. R., Punglia, R. S., Claus, E. B., Lee, E. Q., Wen, P. Y., Haas-Kogan, D. A., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0001 · Cited by 301
Quintana, D. S. (2015) · Frontiers in Psychology · doi:10.3389/fpsyg.2015.01549 · Cited by 260
Pivot, X., Manikhas, A., Żurawski, B., Chmielowska, E., Karaszewska, B., Allerton, R., Chan, S., Fabi, A., Bidoli, P., Gori, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1794 · Cited by 242 · cited 1×
“B Author(s), Year Incidence Rate (patient-years) 95% C.l. Canney 2015 One 2009 Montagna 2009 Gori 2007 Brufsky 2011 Dawson 2011 Pivot 2015 Awada 2016 Bergen 2016 Bian 2013 Witzel 2011 Bartsch 2009 Clayton 2004 Aversa 2014 Kim 2018 Darlix 2019 D’Hondt 2014 Random effects model Heterogeneity: l 2 =…”
BackgroundSwain, S. M., Baselga, J., Miles, D., Im, Y.-H., Quah, C., Lee, L. F., & Cortés, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu133 · Cited by 232
Cortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S.-A., Yusof, M. M., Gallardo, C., Lipatov, O., Barrios, C. H., Holgado, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.1000 · Cited by 186
Cleary, R. J. (2003) · The American Statistician · doi:10.1198/0003130031388 · Cited by 186
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
Brastianos, P. K., Lee, E. Q., Cohen, J. V., Tolaney, S. M., Lin, N., Wang, N., Chukwueke, U. N., White, M. D., Nayyar, N., Kim, A. E., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0918-0 · Cited by 154
Yau, T. C. C., Swanton, C., Chua, S. C., Sue, A., Walsh, G., Rostom, A. Y., Johnston, S. R. D., O'Brien, M. E. R., & Smith, I. E. (2006) · Acta Oncologica · doi:10.1080/02841860500486630 · Cited by 142
Metastatic breast cancer subtypes and central nervous system metastases
Aversa, C., Rossi, V., Geuna, E., Martinello, R., Milani, A., Redana, S., Valabrega, G., Aglietta, M., & Montemurro, F. (2014) · The Breast · doi:10.1016/j.breast.2014.06.009 · Cited by 136
Jin, J., Gao, Y., Zhang, J., Wang, L., Wang, B., Cao, J., Shao, Z., & Wang, Z. (2018) · BMC Cancer · doi:10.1186/s12885-018-4371-0 · Cited by 121
Self-citationKim, Y., Js, K., & Kim, I. A. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2697-2 · Cited by 110
Miles, D. W., Gligorov, J., André, F., Cameron, D., Schneeweiß, A., Barrios, C. H., Xu, B., Wardley, A. M., Kaen, D. L., Andrade, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2243 · Cited by 98
Buparlisib is a brain penetrable pan-PI3K inhibitor
de Gooijer, M. C., Zhang, P., Buil, L. C. M., Çitirikkaya, C. H., Thota, N., Beijnen, J. H., & van Tellingen, O. (2018) · Scientific Reports · doi:10.1038/s41598-018-29062-w · Cited by 83
Ren, J.-X., Gong, Y., Ling, H., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4956-y · Cited by 74
Komorowski, A. S., Warner, E., MacKay, H. J., Sahgal, A., Pritchard, K. I., & Jerzak, K. J. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.06.007 · Cited by 59
Self-citationResponse of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib
Batalini, F., Moulder, S., Winer, E. P., Rugo, H. S., Lin, N., & Wulf, G. M. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00403 · Cited by 46
Nguyen, L. V., Searle, K., & Jerzak, K. J. (2019) · Oncotarget · doi:10.18632/oncotarget.27238 · Cited by 41
Self-citationCanney, P. A., Murray, E., Dixon-Hughes, J., Lewsley, L.-A., & Paul, J. (2015) · Clinical Oncology · doi:10.1016/j.clon.2015.04.033 · Cited by 28
Bian, L., Wang, T., Zhang, S., & Jiang, Z. (2013) · Tumor Biology · doi:10.1007/s13277-013-0884-y · Cited by 11
Survival of patients with metastatic breast cancer: a single-centre experience
D’hondt, R., Spoormans, I., Neyens, N. J. H., Mortier, N., & Aelst, F. V. (2014) · Acta Clinica Belgica · doi:10.1179/2295333714y.0000000016 · Cited by 5
Metadata
- Authors
- Kuksis, M., Gao, Y., Tran, W., Hoey, C., Kiss, A., Komorowski, A. S., Dhaliwal, A. J., Sahgal, A., Das, S., Chan, K. K., & Jerzak, K. J.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-12-23
- Volume
- 23
- Issue
- 6
- Pages
- 894-904
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W3116476506
- Cited by
- 272
- References
- 43
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.